JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us
Esta página ha sido traducida por una máquina. Otras páginas pueden seguir apareciendo en inglés. View in English

Valor terapéutico de los medicamentos oncológicos aprobados por Health Canada a través del Proyecto Orbis: un estudio transversal

  • 0School of Health Policy and Management, York University, Toronto, ON, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.
Journal of Cancer Policy +

|

25 de agosto de 2025

|

25 de agosto de 2025

Ver abstracta en PubMed

Resumen

Este resumen es generado por máquina.

Salud de Canadá

Área De La Ciencia

  • En el campo de la oncología
  • Ciencias de la regulación
  • Política de salud

Sus Antecedentes

  • El proyecto Orbis facilita la colaboración internacional para un acceso más rápido a los tratamientos contra el cáncer.
  • La participación de Health Canada en el Proyecto Orbis tiene como objetivo mejorar el acceso de los pacientes a nuevas terapias.
  • La evaluación del valor terapéutico de los medicamentos aprobados a través del Proyecto Orbis es crucial.

Objetivo Del Estudio

  • Evaluar el valor terapéutico adicional de los medicamentos aprobados por Health Canada a través del Proyecto Orbis.
  • Comparar el valor terapéutico de los medicamentos en función de su tipo de revisión (norma, prioridad, NOC/c).

Principales Métodos

  • Descargado las aprobaciones de medicamentos del Proyecto Orbis de la FDA hasta finales de 2024.
  • Los tipos de participación y aprobación identificados por Health Canada (norma, prioridad, NOC/c).
  • Valor terapéutico adicional evaluado utilizando las calificaciones de las organizaciones internacionales y la prueba Chi-cuadrado.

Principales Resultados

  • Health Canada revisó el 72,1% de los medicamentos del Proyecto Orbis para el 69,6% de las indicaciones.
  • Los medicamentos de revisión prioritaria (69,6%) tenían más probabilidades de ofrecer beneficios terapéuticos moderados o importantes.
  • Los medicamentos con revisiones estándar o condicionales (NOC/c) tenían un valor terapéutico mayor/moderado menos frecuente.

Conclusiones

  • La participación de Health Canada en el Proyecto Orbis debe dar prioridad a los medicamentos elegibles para una revisión prioritaria.
  • Centrarse en las revisiones prioritarias puede optimizar el impacto de la colaboración reguladora internacional.
  • Esta estrategia podría mejorar el acceso de los pacientes a terapias de alto valor para el cáncer.

Palabras clave:

Videos de Conceptos Relacionados

Cancer Therapies 02:49

7.9K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Treatment Resistant Cancers 02:56

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies 02:57

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Prescription, Nonprescription and Orphan Drugs 01:02

844

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...

Clinical Trials: Overview 01:11

3.4K

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Drug Administration and Therapy Phases: Overview 01:26

738

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...